Skip to main content
Michael Caligiuri, MD, Oncology, Duarte, CA

MichaelA.CaligiuriMD

Oncology • Duarte, CA

Immediate Past President, Deana and Steve Campbell Physician-in-Chief Distinguished Chair. Currently Professor, City of Hope National Medical Center

Join to view full profile

Dr. Caligiuri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Caligiuri's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1989
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1983 - 1986
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 1983
  • Stanford University School of Medicine
    Stanford University School of MedicineMA, Physiology, 1980 - 1982
  • State University of New York at Buffalo
    State University of New York at BuffaloBA, Humanities and Health Science, Summa Cum Laude, 1974 - 1978

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2019 - 2025
  • OH State Medical License
    OH State Medical License 1997 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Basic Science Mentor Award American Society of Hematology, 2022
  • Elected Fellow of the AACR Academy The American Association for Cancer Research, 2018
  • Elected Member US National Academy of Medicine, 2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Human AML Activates the AHR Pathway to Impair NK Cell Development and Function  
    Luxi Chen, Michael Zhang, Monica Williams, Jennifer N Saultz, Steven D Scoville, Aharon G Freud, Don M Benson, Michael A Caligiuri, Blood

Abstracts/Posters

  • FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia
    Michael A. Caligiuri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual Meeting
    City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
  • Andrew T. Leitner, M.D., Appointed Chair of City of Hope Department of Supportive Care Medicine
    Andrew T. Leitner, M.D., Appointed Chair of City of Hope Department of Supportive Care MedicineApril 17th, 2023
  • City of Hope Scientists Reveal How XBP1s Interacts with IL-15 to Enhance the Survival of Natural Killer Cells
    City of Hope Scientists Reveal How XBP1s Interacts with IL-15 to Enhance the Survival of Natural Killer CellsMarch 13th, 2023
  • Join now to see all

Grant Support

  • Cancer Center Support GrantNational Cancer Institute2011–2012
  • IL-15 Characterization Through Experimental ImmunologyNational Cancer Institute2010–2012
  • Functional Characterization Of MLL Gene FusionsNational Cancer Institute2002–2012
  • Pre-Clinical And Clinical Investigation Of Mll-Ptd Acute Myeloid LeukemiaNational Cancer Institute2009–2011
  • Innate Immunity: Elucidation And Modulation For Cancer TherapyNational Cancer Institute2007–2011
  • Elucidation &Modulation Of Natural Killer Cell Signaling: Application In CancerNational Cancer Institute2007–2011
  • Oncology Training GrantNational Cancer Institute1998–2011
  • The Ohio State University Comprehensive Cancer CenterNational Cancer Institute2005–2010
  • Cancer And Leukemia Group B - Leukemia Correlative SciencesNational Cancer Institute2009
  • Senior LeadershipNational Cancer Institute2005–2009
  • Protocol Specific Research SupportNational Cancer Institute2005–2009
  • Program Planning &EvaluationNational Cancer Institute2005–2009
  • IL-15 Characterization Through Experimental ImmunologyNational Cancer Institute2005–2009
  • Developmental FundsNational Cancer Institute2005–2009
  • Cancer And Leukemia Group B-Leukemia Correlative ScienceNational Cancer Institute2003–2008
  • The Ohio State University Comprehensive Cancer Center-SupplementNational Cancer Institute2007
  • Administration, Budgeting, And OperationsNational Cancer Institute2007
  • Innate Immunity: Elucidation/Modulation - Cancer TherapyNational Cancer Institute2002–2006
  • A Phase I Study Of Low-Dose Subcutaneous Interleukin 2National Center For Research Resources2004
  • Comprehensive Cancer CenterNational Cancer Institute2003–2004
  • IL 15--Characterization Through Experimental ImmunologyNational Cancer Institute2000–2004
  • Onocology Training GrantNational Cancer Institute1999–2003
  • Immune Regulation By Natural Killer Cell SubsetsNational Cancer Institute2002
  • Novel Immune Modulation In AIDS And AIDS MalignancyNational Cancer Institute2001–2002
  • Therapy For AIDS Central Nervous System LymphomaNational Cancer Institute1999–2002
  • 7th Annual Meeting Of The Society Of Natural ImmunityNational Cancer Institute2001
  • Phase I Study Of G3139 (Nsc 683428) In Combination With Salvage ChemotherapyNational Center For Research Resources2000
  • Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute1999–2000
  • Natural Killer Cell Development And Function In HIV1National Cancer Institute1998–1999
  • Il-15--Characterization Through Experimental ImmunologyNational Cancer Institute1997–1999
  • Biological Response Modifiers In AIDS MalignanciesNational Cancer Institute1997–1998
  • Il-15--Characterization Through Experimental ImmunologyNational Cancer Institute1996
  • Biological Response Modifiers In AIDS MalignanciesNational Cancer Institute1995–1996
  • Cytokines And Lymphomagenesis Of AIDSNational Cancer Institute1994–1996
  • Thymic Derived NK CellsNational Cancer Institute1994
  • Characterization Of Thymic Derived NK CellsNational Cancer Institute1990–1993

Professional Memberships

Dr. Michael Caligiuri, Dr. Michael Caligiuri, MD, Dr. M Caligiuri, Dr. Michael A. Caligiuri